Search

Eric Robert Prossnitz

from Albuquerque, NM
Age ~58
Get Report
Also known as:
Eric R Prossnitz, Eric R Prosnitz
Phone and address:
2705 Rio Orilla Ln, Albuquerque, NM 87120
(505) 899-8314
Related to:
Alexander ProssnitzAlexander N Prossnitz, 28Michael A ProssnitzParaskevi Voula Prossnitz, 63Theodore Gerolimatos, 93Elisavet Gerolimatos, 89Carolina G Cantos, 64
Connected to:
Alan C Prost, 80Emma R Prost, 32Heather L Prost, 37Janet V Prost, 53Patricia A Prost, 85Shannon L Prost, 48Vaughn X Prost, 73Glenn A Prostak, 88Dana L Prostano, 37Stephen Prostano, 33

Eric Prossnitz Phones & Addresses

  • 2705 Rio Orilla Ln, Albuquerque, NM 87120 (505) 899-8314
  • San Diego, CA
  • Berkeley, CA
  • La Jolla, CA
  • 2705 Rio Orilla Ln NW, Albuquerque, NM 87120 (505) 870-3904

Work

Position: Professional/Technical

Education

Degree: High school graduate or higher

Emails

e***[email protected]

Resumes

Resumes

Eric Prossnitz Photo 1

Chief, Division Of Molecular Medicine

View page
Location:
Albuquerque, NM
Industry:
Research
Work:
The University of New Mexico School of Medicine
Chief, Division of Molecular Medicine
University of New Mexico
Professor
The Scripps Research Institute Aug 1994 - Nov 1997
Assistant Professor
Education:
University of California, Berkeley 1985 - 1989
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy University of Victoria 1982 - 1985
Bachelors, Bachelor of Science, Biochemistry
Skills:
Science
Higher Education
University Teaching
Interests:
Science and Technology
Eric Prossnitz Photo 2

Eric Prossnitz

View page

Publications

Us Patents

Display Of Receptors And Analysis Of Binding Interactions And Drug Libraries

View page
US Patent:
7109041, Sep 19, 2006
Filed:
Mar 21, 2002
Appl. No.:
10/101870
Inventors:
Larry Sklar - Albuquerque NM, US
Eric Prossnitz - Albuquerque NM, US
Vilven Janeen - Albuquerque NM, US
Donna Neldon - Los Lunas NM, US
Assignee:
Science & Technology Corporation @University of New Mexico - Albuquerque NM
International Classification:
G01N 33/566
C07K 1/00
C12P 21/02
C12N 1/20
C07H 21/04
US Classification:
436501, 435 721, 435 695, 4352523, 536 242, 536 235, 530402
Abstract:
A display and method of preparing 7-transmembrane and other receptors for real-time kinetic analysis of binding interactions. The invention includes display on beads and in micelles for multi-well and flow cytometric analysis. The invention is useful for ligand discovery and drug action discovery, and G-protein response in particular.

Bead-Based Detection Of Ligand-Gpcr-G Protein Complexes

View page
US Patent:
7189519, Mar 13, 2007
Filed:
May 5, 2003
Appl. No.:
10/429042
Inventors:
Larry A. Sklar - Albuquerque NM, US
Tione Buranda - Albuquerque NM, US
Daniel Cimino - Tijeras NM, US
Alex T. Key - Albuquerque NM, US
Richard Neubig - Scio MI, US
Peter C. Simons - Albuquerque NM, US
Eric R. Prossnitz - Albuquerque NM, US
Mei Shi - Albuquerque NM, US
Assignee:
STC.UNM - Albuquerque NM
Univeristy of Michigan - Ann Arbor MI
International Classification:
G01N 33/52
G01N 33/566
C12N 1/20
C07K 1/00
C07H 21/04
US Classification:
435 71, 436501, 436 56, 436172, 4352523, 530350, 530402, 536 235, 536 242
Abstract:
The present invention provides a general approach for G protein coupled receptors that may be used to define agonists and antagonists, and the specificity of receptor coupling to G protein subunits. Methods of the present invention use small volumes (microliters) and are compatible with high throughput flow cytometry. When assays of the present invention are multiplexed, the specificity of the interactions of a receptor with many G proteins may be determined simultaneously.

Multiplex Analysis For High Throughput Discrimination Of Gpcr Agonists And Antagonists

View page
US Patent:
7232659, Jun 19, 2007
Filed:
Feb 4, 2004
Appl. No.:
10/771853
Inventors:
Larry A. Sklar - Albuquerque NM, US
Eric R. Prossnitz - Albuquerque NM, US
Peter Simons - Albuquerque NM, US
Anna Waller - Albuquerque NM, US
Daniel Cimino - Tijeras NM, US
Sean Biggs - Albuquerque NM, US
Assignee:
STC.UNM - Albuquerque NM
International Classification:
G01N 33/53
G01N 33/566
G01N 27/00
G01N 21/76
C07N 1/00
US Classification:
435 71, 436501, 436 56, 436172, 530350, 530402, 536 235, 435 691
Abstract:
The present invention relates generally to molecular assemblies, more particularly to an assay for the detection of G-protein coupled receptor (GPCR) molecular assemblies and bead-based detection of ligand-GPCR complexes and to methods for identifying compounds as agonists, partial agonists or antagonists of the binding of G-protein coupled receptors to G-protein and for use of these compounds in the treatment of conditions or disease states in a mammalian subject or patient, including humans, where G-protein coupled receptor binding to G-protein is implicated.

Glutathione Beads And Gst Fusion Proteins

View page
US Patent:
7785900, Aug 31, 2010
Filed:
Jan 11, 2007
Appl. No.:
11/652432
Inventors:
Peter C. Simons - Albuquerque NM, US
Larry A. Sklar - Albuquerque NM, US
Eric R. Prossnitz - Albuquerque NM, US
Mathewos Z. Tessema - Albuquerque NM, US
John C. Reed - Ranch Santa Fe CA, US
Dayong Zhai - San Diego CA, US
Assignee:
STC.UNM - Albuquerque NM
Sanford-Burnham Medical Research Institute - La Jolla CA
International Classification:
G01N 33/543
G01N 33/53
US Classification:
436523, 436501, 436506, 436518, 436524, 436528, 435 71, 435 721, 422 50, 422 61, 424 91, 530300, 530350
Abstract:
The present invention relates generally to glutathione derivatized beads which are adapted for use in conjunction with glutathione-S-transferase fusion proteins (generally, GST fusion proteins, which contain a fluorescent label such as fluorescent green protein) for use in flow cytometry. The present invention also relates to methods for detecting and/or quantifying interactions between a GST fusion protein and their binding partners, in particular, labeled binding partners such as fluorescently labeled binding partners. By creating glutathione beads with an appropriate high or increased site density, disadvantages often associated with low affinity systems and quick off-rates in solution may be resolved to provide a workable system and method. Methods of identifying potential agonists, antagonists and regulator compounds of proteins fused to GST from libraries of compounds represents another aspect of the present invention.

Compounds For Binding To Erα/Β And Gpr30, Methods Of Treating Disease States And Conditions Mediated Through These Receptors And Identification Thereof

View page
US Patent:
7875721, Jan 25, 2011
Filed:
Aug 2, 2006
Appl. No.:
11/497751
Inventors:
Eric R. Prossnitz - Albuquerque NM, US
Sergey E. Tkatchenko - San Diego CA, US
Chetana M. Revankar - Arlington VA, US
Larry A. Sklar - Albuquerque NM, US
Jeffrey B. Arterburn - Las Cruces NM, US
Daniel F. Cimino - Tijeras NM, US
Tudor I. Oprea - Albuquerque NM, US
Bruce S. Edwards - Albuquerque NM, US
Alexander Kiselyov - San Diego CA, US
Susan M. Young - Albuquerque NM, US
Assignee:
STC.UNM - Albuquerque NM
International Classification:
A61K 31/435
C07D 221/06
US Classification:
546 79, 514290
Abstract:
The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

Compounds For Binding To Er Alpha/Beta And Gpr30, Methods Of Treating Disease States And Conditions Mediated Through These Receptors And Identification Thereof

View page
US Patent:
8487100, Jul 16, 2013
Filed:
Dec 14, 2010
Appl. No.:
12/967871
Inventors:
Eric R Prossnitz - Albuquerque NM, US
Sergey E Tkatchenko - San Diego CA, US
Chetana M Revankar - Arlington VA, US
Larry A Sklar - Albuquerque NM, US
Jeffrey B Arterburn - Las Cruces NM, US
Daniel F Cimino - Tijeras NM, US
Tudor I Oprea - Albuquerque NM, US
Bruce S Edwards - Albuquerque NM, US
Alexandor Kiselyov - San Diego CA, US
Susan M Young - Albuquerque NM, US
Assignee:
STC.UNM - Albuquerque NM
International Classification:
A61K 31/4375
C07D 221/06
US Classification:
546 79, 514290
Abstract:
The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometreitis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disoders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

Display Of Receptors And Analysis Of Binding Interactions And Drug Libraries

View page
US Patent:
7018846, Mar 28, 2006
Filed:
Aug 9, 1999
Appl. No.:
09/370358
Inventors:
Larry A. Sklar - Albuquerque NM, US
Eric Prossnitz - Albuquerque NM, US
Janeen Vilven - Albuquerque NM, US
Donna Neldon - Albuquerque NM, US
Assignee:
Science & Technology Corporation @ UNM - Albuquerque NM
International Classification:
G01N 33/566
C07K 1/00
C12P 21/02
C12N 1/20
C07H 21/04
US Classification:
436501, 435 721, 435 695, 4352523, 536 235, 536 242, 530350, 530402
Abstract:
A display and method of preparing 7-transmembrane and other receptors for real-time kinetic analysis of binding interactions. The invention includes display on beads and in micelles for multi-well and flow cytometric analysis. The invention is useful for ligand discovery and drug action discovery, and G-protein response in particular.
Control profile
Eric Robert Prossnitz from Albuquerque, NM, age ~58 Get Report